Postprandial macrophage-derived IL-1β stimulates insulin, and both synergistically promote glucose disposal and inflammation

Nature Immunology

Volumn 18, Issue 3, 2017, Pages 283-292

  Dror, Erez ^a,f   Dalmas, Elise ^a,f   Meier, Daniel T ^a,f   Wueest, Stephan ^b   Thévenet, Julien ^c,g   Thienel, Constanze ^a,f   Timper, Katharina ^a,f   Nordmann, Thierry M ^a,f   Traub, Shuyang ^a,f   Schulze, Friederike ^a,f   Item, Flurin ^b   Vallois, David ^d   Pattou, Francois ^c,g   Kerr Conte, Julie ^c,g   Lavallard, Vanessa ^e,h   Berney, Thierry ^e,h   Thorens, Bernard ^d   Konrad, Daniel ^b   Böni Schnetzler, Marianne ^a,f   Donath, Marc Y ^a,f  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^c UNIV LILLE   (France)

^d UNIVERSITY OF LAUSANNE   (Switzerland)

^e GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^f UNIVERSITY OF BASEL   (Switzerland)

^g European Genomic Institute for Diabetes ^*  (France)

^h UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANAKINRA; CANAGLIFLOZIN; CRYOPYRIN; DEOXYGLUCOSE; INSULIN RECEPTOR; INTERLEUKIN 1BETA; LIPOPOLYSACCHARIDE; REACTIVE OXYGEN METABOLITE; SODIUM GLUCOSE COTRANSPORTER 2; GLUCOSE; INFLAMMASOME; INSULIN; NLRP3 PROTEIN, MOUSE; SLC5A2 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DEATH; CONTROLLED STUDY; CYTOKINE RELEASE; DIET INDUCED OBESITY; FEEDING; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSE TOLERANCE TEST; GLUCOSE TRANSPORT; GLUCOSE URINE LEVEL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCOMPETENT CELL; INFLAMMATION; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN SENSITIVITY; INSULIN TOLERANCE TEST; LIPID DIET; MALE; MOUSE; NONHUMAN; PANCREAS ISLET; PERITONEUM MACROPHAGE; POSTPRANDIAL STATE; PRIORITY JOURNAL; PROTEIN FUNCTION; REFEEDING; SIGNAL TRANSDUCTION; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; CELL CULTURE; GENETICS; IMMUNOLOGY; KNOCKOUT MOUSE; MACROPHAGE; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PHYSIOLOGY;

ANIMALS; CELLS, CULTURED; DIABETES MELLITUS, TYPE 2; GLUCOSE; HUMANS; INFLAMMASOMES; INFLAMMATION; INSULIN; INSULIN-SECRETING CELLS; INTERLEUKIN-1BETA; MACROPHAGES; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; NLR FAMILY, PYRIN DOMAIN-CONTAINING 3 PROTEIN; POSTPRANDIAL PERIOD; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 85009810559     PISSN: 15292908     EISSN: 15292916     Source Type: Journal    
DOI: 10.1038/ni.3659     Document Type: Article

References (57)

1. Dinarello, C. A. Multiple biological properties of recombinant human interleukin 1 (). Immunobiology 172, 301-315 (1986).
2. Wellen, K. E. & Hotamisligil, G. S. Inflammation, stress, and diabetes. J. Clin. Invest. 115, 1111-1119 (2005).
3. Hotamisligil, G. S., Shargill, N. S. & Spiegelman, B. M. Adipose expression of tumor necrosis factor-: direct role in obesity-linked insulin resistance. Science 259, 87-91 (1993).
4. Donath, M. Y., Dalmas, É., Sauter, N. S. & Böni-Schnetzler, M. Inflammation in obesity and diabetes: islet dysfunction and therapeutic opportunity. Cell Metab. 17, 860-872 (2013).
5. Ehses, J. A., Böni-Schnetzler, M., Faulenbach, M. & Donath, M. Y. Macrophages, cytokines and beta-cell death in Type 2 diabetes. Biochem. Soc. Trans. 36, 340-342 (2008).
6. Donath, M. Y. & Shoelson, S. E. Type 2 diabetes as an inflammatory disease. Nat. Rev. Immunol. 11, 98-107 (2011).
7. Martinon, F., Pétrilli, V., Mayor, A., Tardivel, A. & Tschopp, J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440, 237-241 (2006).
8. Duewell, P. et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 464, 1357-1361 (2010).
9. Vandanmagsar, B. et al. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat. Med. 17, 179-188 (2011).
10. Wen, H. et al. Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling. Nat. Immunol. 12, 408-415 (2011).
11. Stienstra, R. et al. The inflammasome-mediated caspase-1 activation controls adipocyte differentiation and insulin sensitivity. Cell Metab. 12, 593-605 (2010).
12. Maedler, K. et al. Glucose-induced beta cell production of IL-1 contributes to glucotoxicity in human pancreatic islets. J. Clin. Invest. 110, 851-860 (2002).
13. Masters, S. L. et al. Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1 in type 2 diabetes. Nat. Immunol. 11, 897-904 (2010).
14. Zhou, R., Tardivel, A., Thorens, B., Choi, I. & Tschopp, J. Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat. Immunol. 11, 136-140 (2010).
15. Stienstra, R. et al. Inflammasome is a central player in the induction of obesity and insulin resistance. Proc. Natl. Acad. Sci. USA 108, 15324-15329 (2011).
16. Ehses, J. A. et al. IL-1 antagonism reduces hyperglycemia and tissue inflammation in the type 2 diabetic GK rat. Proc. Natl. Acad. Sci. USA 106, 13998-14003 (2009).
17. Larsen, C. M. et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N. Engl. J. Med. 356, 1517-1526 (2007).
18. van Asseldonk, E. J. et al. Treatment with Anakinra improves disposition index but not insulin sensitivity in nondiabetic subjects with the metabolic syndrome: a randomized, double-blind, placebo-controlled study. J. Clin. Endocrinol. Metab. 96, 2119-2126 (2011).
19. Cavelti-Weder, C. et al. Effects of gevokizumab on glycemia and inflammatory markers in type 2 diabetes. Diabetes Care 35, 1654-1662 (2012).
20. Hensen, J., Howard, C. P., Walter, V. & Thuren, T. Impact of interleukin-1 antibody (canakinumab) on glycaemic indicators in patients with type 2 diabetes mellitus: results of secondary endpoints from a randomized, placebo-controlled trial. Diabetes Metab. 39, 524-531 (2013).
21. Sloan-Lancaster, J. et al. Double-blind, randomized study evaluating the glycemic and anti-inflammatory effects of subcutaneous LY2189102, a neutralizing IL-1 antibody, in patients with type 2 diabetes. Diabetes Care 36, 2239-2246 (2013).
22. Gubser, P. M. et al. Rapid effector function of memory CD8+ T cells requires an immediate-early glycolytic switch. Nat. Immunol. 14, 1064-1072 (2013).
23. Fox, C. J., Hammerman, P. S. & Thompson, C. B. Fuel feeds function: energy metabolism and the T-cell response. Nat. Rev. Immunol. 5, 844-852 (2005).
24. Macintyre, A. N. et al. The glucose transporter Glut1 is selectively essential for CD4 T cell activation and effector function. Cell Metab. 20, 61-72 (2014).
25. Freemerman, A. J. et al. Metabolic reprogramming of macrophages: glucose transporter 1 (GLUT1)-mediated glucose metabolism drives a proinflammatory phenotype. J. Biol. Chem. 289, 7884-7896 (2014).
26. Tannahill, G. M. et al. Succinate is an inflammatory signal that induces IL-1(through HIF-1. Nature 496, 238-242 (2013).
27. Böni-Schnetzler, M. et al. Free fatty acids induce a proinflammatory response in islets via the abundantly expressed interleukin-1 receptor I. Endocrinology 150, 5218-5229 (2009).
28. Benner, C. et al. The transcriptional landscape of mouse beta cells compared to human beta cells reveals notable species differences in long non-coding RNA and protein-coding gene expression. BMC Genomics 15, 620 (2014).
29. Bendtzen, K. et al. Cytotoxicity of human pI 7 interleukin-1 for pancreatic islets of Langerhans. Science 232, 1545-1547 (1986).
30. Mandrup-Poulsen, T. et al. Affinity-purified human interleukin I is cytotoxic to isolated islets of Langerhans. Diabetologia 29, 63-67 (1986).
31. Zawalich, W. S. & Zawalich, K. C. Interleukin 1 is a potent stimulator of islet insulin secretion and phosphoinositide hydrolysis. Am. J. Physiol. 256, E19-E24 (1989).
32. Donath, M. Y., Böni-Schnetzler, M., Ellingsgaard, H., Halban, P. A. & Ehses, J. A. Cytokine production by islets in health and diabetes: cellular origin, regulation and function. Trends Endocrinol. Metab. 21, 261-267 (2010).
33. Caumo, A. & Luzi, L. First-phase insulin secretion: does it exist in real life Considerations on shape and function. Am. J. Physiol. Endocrinol. Metab. 287, E371-E385 (2004).
34. Baggio, L. L. & Drucker, D. J. Biology of incretins: GLP-1 and GIP. Gastroenterology 132, 2131-2157 (2007).
35. Van Oostrom, A. J., Sijmonsma, T. P., Rabelink, T. J., Van Asbeck, B. S. & Cabezas, M. C. Postprandial leukocyte increase in healthy subjects. Metabolism 52, 199-202 (2003).
36. Herieka, M. & Erridge, C. High-fat meal induced postprandial inflammation. Mol. Nutr. Food Res. 58, 136-146 (2014).
37. Pétrilli, V. et al. Activation of the NALP3 inflammasome is triggered by low intracellular potassium concentration. Cell Death Differ. 14, 1583-1589 (2007).
38. Okabe, Y. & Medzhitov, R. Tissue-specific signals control reversible program of localization and functional polarization of macrophages. Cell 157, 832-844 (2014).
39. Platell, C., Cooper, D., Papadimitriou, J. M. & Hall, J. C. The omentum. World J. Gasteroenterol. 6, 169-176 (2000).
40. Shrivastava, P. & Bhatia, M. Essential role of monocytes and macrophages in the progression of acute pancreatitis. World J. Gasteroenterol. 16, 3995-4002 (2010).
41. Cani, P. D. et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 56, 1761-1772 (2007).
42. Breton, J. et al. Gut commensal E. coli proteins activate host satiety pathways following nutrient-induced bacterial growth. Cell Metab. 23, 324-334 (2016).
43. Zhang, D. et al. Neutrophil ageing is regulated by the microbiome. Nature 525, 528-532 (2015).
44. Corbett, J. A., Wang, J. L., Sweetland, M. A., Lancaster, J. R. Jr. & McDaniel, M. L. Interleukin 1 induces the formation of nitric oxide by beta-cells purified from rodent islets of Langerhans. Evidence for the beta-cell as a source and site of action of nitric oxide. J. Clin. Invest. 90, 2384-2391 (1992).
45. Hajmrle, C. et al. Interleukin-1 signaling contributes to acute islet compensation. J. Clin. Invest. 1, e86055 (2016).
46. Greenwood, R. H., Mahler, R. F. & Hales, C. N. Improvement in insulin secretion in diabetes after diazoxide. Lancet 1, 444-447 (1976).
47. Olefsky, J. M. & Glass, C. K. Macrophages, inflammation, and insulin resistance. Annu. Rev. Physiol. 72, 219-246 (2010).
48. Mauer, J. et al. Myeloid cell-restricted insulin receptor deficiency protects against obesity-induced inflammation and systemic insulin resistance. PLoS Genet. 6, e1000938 (2010).
49. Costa Rosa, L. F., Safi, D. A., Cury, Y. & Curi, R. The effect of insulin on macrophage metabolism and function. Cell Biochem. Funct. 14, 33-42 (1996).
50. Zinman, B. et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med. 373, 2117-2128 (2015).
51. Ravassard, P. et al. A genetically engineered human pancreatic cell line exhibiting glucose-inducible insulin secretion. J. Clin. Invest. 121, 3589-3597 (2011).
52. Horai, R. et al. Production of mice deficient in genes for interleukin (IL)-1, IL-1, IL-1/, and IL-1 receptor antagonist shows that IL-1 is crucial in turpentine-induced fever development and glucocorticoid secretion. J. Exp. Med. 187, 1463-1475 (1998).
53. Farley, F. W., Soriano, P., Steffen, L. S. & Dymecki, S. M. Widespread recombinase expression using FLPeR (flipper) mice. Genesis 28, 106-110 (2000).
54. Clausen, B. E., Burkhardt, C., Reith, W., Renkawitz, R. & Förster, I. Conditional gene targeting in macrophages and granulocytes using LysMcre mice. Transgenic Res. 8, 265-277 (1999).
55. Preitner, F. et al. Gluco-incretins control insulin secretion at multiple levels as revealed in mice lacking GLP-1 and GIP receptors. J. Clin. Invest. 113, 635-645 (2004).
56. Wueest, S. et al. Fas (CD95) expression in myeloid cells promotes obesityinduced muscle insulin resistance. EMBO Mol. Med. 6, 43-56 (2014).
57. Caiazzo, R. et al. Quantitative in vivo islet potency assay in normoglycemic nude mice correlates with primary graft function after clinical transplantation. Transplantation 86, 360-363 (2008).